SG11201701645WA - Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia - Google Patents

Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Info

Publication number
SG11201701645WA
SG11201701645WA SG11201701645WA SG11201701645WA SG11201701645WA SG 11201701645W A SG11201701645W A SG 11201701645WA SG 11201701645W A SG11201701645W A SG 11201701645WA SG 11201701645W A SG11201701645W A SG 11201701645WA SG 11201701645W A SG11201701645W A SG 11201701645WA
Authority
SG
Singapore
Prior art keywords
quinidine
dementia
agitation
treatment
pharmaceutical compositions
Prior art date
Application number
SG11201701645WA
Other languages
English (en)
Inventor
Joao Siffert
Original Assignee
Avanir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avanir Pharmaceuticals Inc filed Critical Avanir Pharmaceuticals Inc
Publication of SG11201701645WA publication Critical patent/SG11201701645WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/49Cinchonan derivatives, e.g. quinine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22Bridged ring systems
    • C07D221/28Morphinans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201701645WA 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia SG11201701645WA (en)

Applications Claiming Priority (18)

Application Number Priority Date Filing Date Title
US201462050170P 2014-09-14 2014-09-14
US201462061451P 2014-10-08 2014-10-08
US201462063122P 2014-10-13 2014-10-13
US201462063861P 2014-10-14 2014-10-14
US201462068742P 2014-10-26 2014-10-26
US201562111053P 2015-02-02 2015-02-02
US201562111590P 2015-02-03 2015-02-03
US201562128446P 2015-03-04 2015-03-04
US201562162140P 2015-05-15 2015-05-15
US201562165535P 2015-05-22 2015-05-22
US201562169997P 2015-06-02 2015-06-02
US201562180026P 2015-06-15 2015-06-15
US201562193347P 2015-07-16 2015-07-16
US201562205061P 2015-08-14 2015-08-14
US201562216636P 2015-09-10 2015-09-10
US201562217142P 2015-09-11 2015-09-11
US201562217470P 2015-09-11 2015-09-11
PCT/US2015/049934 WO2016040930A1 (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Publications (1)

Publication Number Publication Date
SG11201701645WA true SG11201701645WA (en) 2017-04-27

Family

ID=55459653

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201701645WA SG11201701645WA (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
SG10201901242PA SG10201901242PA (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201901242PA SG10201901242PA (en) 2014-09-14 2015-09-14 Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia

Country Status (15)

Country Link
US (3) US20190111047A1 (https=)
EP (4) EP3193872A4 (https=)
JP (4) JP2017531033A (https=)
KR (1) KR20170052684A (https=)
CN (3) CN117427077A (https=)
AU (3) AU2015314710A1 (https=)
CA (1) CA2960031A1 (https=)
IL (2) IL250786A0 (https=)
MX (3) MX2017003066A (https=)
MY (1) MY198587A (https=)
PH (1) PH12017500444A1 (https=)
RU (1) RU2017112747A (https=)
SG (2) SG11201701645WA (https=)
TW (3) TW202106301A (https=)
WO (1) WO2016040930A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2357183B1 (en) 2007-05-01 2015-07-01 Concert Pharmaceuticals Inc. Morphinan compounds
CA2994153A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
WO2017020002A1 (en) * 2015-07-30 2017-02-02 Concert Pharmaceuticals, Inc. Deuterated morphinan compounds for use in treating agitation
ES2925277T3 (es) * 2016-07-04 2022-10-14 Avanir Pharmaceuticals Inc Métodos para la síntesis de dextrometorfano deuterado
CN110831584B (zh) * 2017-05-04 2023-03-10 埃克塞瓦有限责任公司 具有新颖的组合物、组合的靶向药物拯救及其方法
US11478467B2 (en) 2017-05-04 2022-10-25 Sreenivasarao Vepachedu Targeted drug rescue with novel compositions, combinations, and methods thereof
AU2019269739B2 (en) 2018-05-18 2025-12-18 Anavex Life Sciences Corp. Optimized sigma-1 agonist method of responder selection and treatment
SMT202600055T1 (it) * 2019-01-07 2026-03-09 Antecip Bioventures Ii Llc Combinazione di destrometorfano e bupropione per trattare la depressione in pazienti asiatici
AU2020241611A1 (en) * 2019-03-18 2021-11-04 Avanir Pharmaceuticals, Inc. Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine
US20230270738A1 (en) * 2020-04-27 2023-08-31 Avanir Phrmaceuticals Inc. Methods of treating agitation associated with alzheimer's disease
CN115245515A (zh) * 2021-04-27 2022-10-28 杭州剂泰医药科技有限责任公司 一种组合物的医药用途
CN115322150B (zh) * 2021-05-11 2024-05-28 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
CN113209042A (zh) * 2021-05-28 2021-08-06 珠海润都制药股份有限公司 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法
IL312310A (en) * 2021-10-27 2024-06-01 Avanir Pharmaceuticals Inc Methods for treating agitation associated with Alzheimer's disease
CN116459255A (zh) * 2022-01-19 2023-07-21 深圳信立泰药业股份有限公司 氘代右美沙芬与安非他酮联合在制备ad激越的药物中的用途
US11730706B1 (en) * 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
CN117783322A (zh) * 2022-12-16 2024-03-29 杭州剂泰医药科技有限责任公司 右美沙芬奎尼丁组合物的hplc分析方法
KR20250120917A (ko) 2024-02-02 2025-08-11 단국대학교 천안캠퍼스 산학협력단 덱스트로메토르판을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물
KR20250129211A (ko) 2024-02-22 2025-08-29 단국대학교 천안캠퍼스 산학협력단 데가렐릭스를 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학적 조성물

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US5166207A (en) 1991-06-17 1992-11-24 Neurotherapeutics, Inc. Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders
US5206248A (en) 1992-03-27 1993-04-27 Smith Richard A Method for reducing emotional lability
US5366980A (en) 1991-06-17 1994-11-22 Smith Richard A Use of dextromethorphan and an oxidase inhibitor to treat dermatitis
US5350756A (en) 1991-06-17 1994-09-27 Smith Richard A Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan
TW264473B (https=) * 1993-01-06 1995-12-01 Hoffmann La Roche
JP4097285B2 (ja) * 1994-09-22 2008-06-11 リチャード・アラン・スミス 種々の頑固な疾患の治療のための医薬の製造に有用な組成物
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
EP1032377B1 (en) 1997-11-21 2010-11-17 Purdue Neuroscience Company Substituted 2-aminoacetamides and the use thereof
BR9909146A (pt) 1998-03-26 2000-12-05 Shionogi & Co Derivados de indol apresentando uma atividade antiviral
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
EP1986639A4 (en) * 2006-02-03 2010-04-28 Avanir Pharmaceuticals PHARMACEUTICAL COMPOSITIONS OF DEXTROMETHORPHANE AND CHINIDINE FOR THE TREATMENT OF DEPRESSION, FEAR STATES AND NEURODEEGENERATIVE DISEASES
WO2007103474A2 (en) * 2006-03-07 2007-09-13 University Of Florida Research Foundation, Inc. Drug adherence monitoring system
WO2008097924A2 (en) * 2007-02-05 2008-08-14 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
EP2357183B1 (en) * 2007-05-01 2015-07-01 Concert Pharmaceuticals Inc. Morphinan compounds
MX370608B (es) * 2007-05-01 2019-12-18 Concert Pharmaceuticals Inc Compuestos de morfinano.
DK2418211T3 (en) * 2008-09-19 2016-06-27 Concert Pharmaceuticals Inc DEUTERATED MORPHINAN COMPOUNDS
US20120083487A1 (en) * 2008-10-30 2012-04-05 Amanda Thomas Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurolgical diseases, intractable and chronic pain and brain injury
JP5647615B2 (ja) * 2008-11-14 2015-01-07 コンサート ファーマシューティカルズ インコーポレイテッド 置換ジオキソピペリジニルフタルイミド誘導体
MY179696A (en) * 2013-11-05 2020-11-11 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds and dextromethorphan

Also Published As

Publication number Publication date
TW201613591A (en) 2016-04-16
EP3932907A3 (en) 2022-03-30
US20190111047A1 (en) 2019-04-18
SG10201901242PA (en) 2019-03-28
JP2020019818A (ja) 2020-02-06
KR20170052684A (ko) 2017-05-12
MX2017003066A (es) 2017-09-12
IL274742A (en) 2020-07-30
JP7360409B2 (ja) 2023-10-12
US20200289499A1 (en) 2020-09-17
RU2017112747A (ru) 2018-10-15
EP3932907A2 (en) 2022-01-05
EP4166141A1 (en) 2023-04-19
RU2017112747A3 (https=) 2019-04-29
AU2015314710A1 (en) 2017-04-20
CN110664801A (zh) 2020-01-10
EP3193872A1 (en) 2017-07-26
JP2023105265A (ja) 2023-07-28
CA2960031A1 (en) 2016-03-17
MX2021010696A (es) 2021-10-01
RU2020116666A (ru) 2020-07-31
EP3193872A4 (en) 2018-02-28
MX2022008181A (es) 2022-08-10
US20240082237A1 (en) 2024-03-14
JP2021080300A (ja) 2021-05-27
CN107072990A (zh) 2017-08-18
PH12017500444A1 (en) 2017-07-31
WO2016040930A1 (en) 2016-03-17
JP2017531033A (ja) 2017-10-19
TWI869633B (zh) 2025-01-11
TW202231278A (zh) 2022-08-16
AU2022283671B2 (en) 2025-03-20
IL250786A0 (en) 2017-04-30
EP3708168A2 (en) 2020-09-16
CN117427077A (zh) 2024-01-23
TW202106301A (zh) 2021-02-16
MY198587A (en) 2023-09-06
EP3708168A3 (en) 2020-12-09
AU2022283671A1 (en) 2023-02-02
AU2020289733A1 (en) 2021-01-21

Similar Documents

Publication Publication Date Title
IL274742A (en) Pharmaceutical preparations containing the compound dextromethorphan and quinidine for the treatment of restlessness in dementia
IL272820B (en) The history of sulfamoylpyrrolamide and their use as drugs to treat jaundice b
IL260257A (en) Preparations and methods for the treatment of hemoglobinopathies
IL256085B (en) A converted derivative of huanic acid, a pharmaceutical preparation containing it and the converted derivative for use in treatment
IL256296A (en) Particles of dimethyl fumarate and pharmaceutical preparations thereof
PL3515420T3 (pl) Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
ZA201707303B (en) Compositions and methods for the treatment of immunodeficiency
GB201400442D0 (en) Compositions for use in the treatment of ulcerative colitis
IL265970B (en) Sulfoxyalkyl organonitro compounds and related compounds and pharmaceutical preparations for use in medicine
IL264167A (en) Preparations and methods for the treatment of frontotemporal dementia
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
IL249364A0 (en) Pharmaceutical preparations that include dgla and their use
LT3373922T (lt) Kompozicijos ir būdai skirti naudoti homocistinurijos gydyme
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
SG10202106375UA (en) Pharmaceutical compositions and use thereof
PL3842436T3 (pl) Kompozycje farmaceutyczne zawierające imidazopirymdynę lub pochodne imidazotriazyny do zastosowania w leczeniu schizofrenii
IL280389A (en) Bile acid receptor modulators conjugated to G.1 protein and methods of using them
IL249440B (en) Pharmaceutical compounds and preparations containing them for the treatment of neurodegenerative diseases
SG11201609701UA (en) Pharmaceutical composition for preventing and treating senile dementia and preparation method thereof
PT3548006T (pt) Composição para utilização no tratamento de alterações intestinais
HK1238554A1 (en) Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia
IL257689B (en) Pharmaceutical preparations and methods for treating diseases related to lack of oxygen
GB201616880D0 (en) Compound for use in medicine
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
HK40013407A (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine